BREAST CANCER · White paper
Breast Cancer Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About breast cancer — and why its trials are hard
Breast cancer is not one disease but a group of molecular subtypes, chiefly hormone receptor-positive, HER2-positive, and triple-negative, each with distinct prognosis and treatment. Diagnosis has moved from purely morphologic staging to receptor and genetic profiling (ER, PR, HER2, BRCA1/2), enabling targeted and personalized therapy. The therapeutic arc runs from endocrine therapy (tamoxifen, aromatase inhibitors) through HER2-directed antibodies and antibody-drug conjugates, CDK4/6 inhibitors for HR-positive advanced disease, and immunotherapy for triple-negative disease. Pivotal trials define the modern standard: HERA and B-31 for trastuzumab, CLEOPATRA for pertuzumab, EMILIA for T-DM1, PALOMA for palbociclib, and KEYNOTE-522 for pembrolizumab. Trial endpoints span disease-free and recurrence-free survival in the adjuvant setting, pathologic complete response in neoadjuvant studies, and progression-free and overall survival in metastatic disease. Persistent design challenges include subtype heterogeneity, biomarker validation, and dosing optimization. Failures, most notably bevacizumab, illustrate how a progression-free survival benefit without an overall survival gain can lead to indication withdrawal.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Tamoxifen (Nolvadex/Soltamox) | 1977 | Hormone receptor-positive breast cancer, adjuvant and treatment | Large adjuvant endocrine trials (EBCTCG overview) | Recurrence and mortality reduction | Substantial reductions in recurrence and breast-cancer mortality with ~5 years of therapy |
| Trastuzumab (Herceptin) | 1998 | HER2-overexpressing breast cancer, adjuvant and metastatic | HERA, NSABP B-31/NCCTG N9831 | Disease-free survival | DFS hazard ratio approximately 0.54 in adjuvant setting |
| Pertuzumab (Perjeta) | 2012 | HER2-positive metastatic (and later neoadjuvant/adjuvant), with trastuzumab + docetaxel | CLEOPATRA | Overall survival | Median OS 57.1 vs 40.8 months |
| Ado-trastuzumab emtansine (Kadcyla (T-DM1)) | 2013 | HER2-positive metastatic after trastuzumab/taxane | EMILIA | PFS and OS | PFS 9.6 vs 6.4 months; OS improved vs lapatinib + capecitabine |
| Palbociclib (Ibrance) | 2015 | HR-positive, HER2-negative advanced breast cancer with endocrine therapy | PALOMA-3 (with fulvestrant) | Progression-free survival | Significant PFS improvement vs fulvestrant plus placebo |
| Pembrolizumab (Keytruda) | 2021 | High-risk early triple-negative breast cancer, neoadjuvant/adjuvant | KEYNOTE-522 | Pathologic complete response and EFS | pCR 64.8% vs 51.2% |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in breast cancer development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Bevacizumab — E2100 | PFS gain without overall survival benefit; breast cancer indication withdrawn in 2011 | Progression-free survival did not translate to survival and toxicity outweighed benefit, prompting FDA revocation |
| Iniparib — NCT00938652 (BSI-201, metastatic TNBC) | Failed to meet co-primary OS and PFS endpoints with gemcitabine/carboplatin | Compound was not a true PARP inhibitor as initially believed; mechanism misclassification undermined the program |
| Sunitinib malate — NCT00435409 | Capecitabine plus sunitinib not effective in reducing tumor growth in metastatic breast cancer | Anti-angiogenic tyrosine kinase inhibition added toxicity without efficacy gains in breast cancer |
Choosing the right endpoint
Primary endpoints that matter in breast cancer trials
- Pathologic complete response (pCR) — Neoadjuvant surrogate, central to KEYNOTE-522 and accelerated approvals
- Disease-free / recurrence-free survival — Primary adjuvant endpoints (e.g., trastuzumab DFS)
- Overall survival — Definitive benefit measure, as in CLEOPATRA; long follow-up required
- Progression-free survival — Key metastatic endpoint but, as bevacizumab showed, may not predict OS
- Biomarker-defined response (ER/PR/HER2) — Receptor status stratifies patients and defines eligible targeted populations
How iNGENū runs breast cancer trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Breast Cancer clinical trials — FAQs
Why was bevacizumab's breast cancer approval withdrawn?
What is pathologic complete response and why does it matter?
How has biomarker profiling changed breast cancer trials?
Ready to discuss your breast cancer trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal